Saturday 17 October 2026
Export LEGN’s income statement to Excel — free account
Legend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024. In the quarter to June 2026, revenue grew 51.9%, EPS grew 126.1%, free cash flow fell 26.8% and total debt fell 49.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
18.48
1.32
−6.67%
Follow LEGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.25 | 2.94 | 3.89 | 6.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(258.40) | (39.35) | (328.32) | 209.03 | |
P/B ratio |
4.39 | 3.46 | 4.00 | 5.95 | |
Price to Tangible BV |
4.40 | 3.47 | 4.01 | 5.97 | |
EV/Sales |
3.75 | 2.59 | 3.45 | 5.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(53.29) | (36.13) | (35.42) | (31.42) | |
EV/FCF |
(38.93) | (25.36) | (27.43) | (28.24) | |
Quick Ratio |
2.39 | 1.64 | 1.51 | 2.29 | |
Current Ratio |
3.04 | 2.13 | 1.96 | 2.86 | |
Net Debt/EBITDA |
(11.99) | 14.47 | 62.74 | 18.29 | |
Debt/Assets |
8.93% | 16.66% | 18.41% | 18.38% | |
Debt/Equity |
0.13 | 0.27 | 0.32 | 0.31 | |
Asset Turnover |
0.74 | 0.71 | 0.60 | 0.53 | |
Operating CF/Net income |
(0.63) | 1.57 | 0.40 | (0.73) | |
Capex/Depreciation |
(0.64) | (0.48) | (1.03) | (0.83) | |
Research and Development Expense of Revenue |
24.77% | 28.09% | 33.07% | 41.55% | |
Selling, General and Administrative Expense of Revenue |
24.88% | 29.53% | 32.98% | 32.07% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.13 | 0.14 | 0.13 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.72%) | (7.49%) | (7.41%) | (3.99%) | |
Free Cash Flow Yield |
(2.27%) | (3.48%) | (3.23%) | (3.14%) | |
Revenue per Share |
2.07 | 1.65 | 1.66 | 1.47 | |
Operating CF per Share |
(0.11) | (0.46) | (0.07) | 0.16 | |
Capex per Share |
(0.04) | (0.04) | (0.07) | (0.03) | |
Free Cash Flow per Share |
(0.15) | (0.50) | (0.13) | 0.13 | |
Cash per Share |
5.16 | 4.51 | 5.15 | 5.38 | |
Shareholders Equity per Share |
6.58 | 5.23 | 5.44 | 5.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.58 | 5.23 | 5.44 | 5.48 | |
Free Cash Flow |
(28.40) | (92.60) | (24.57) | 23.77 | |
Working Capital |
823.80 | 573.60 | 610.70 | 808.43 | |
Capital Expenditures |
(7.50) | (7.50) | (12.37) | (5.03) | |
Net Current Asset Value |
706.10 | 453.70 | 515.50 | 540.32 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.04 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 1.03 | 9.75 | 0.97 | |
Average Payables |
76.33 | 66.22 | 60.80 | 64.68 | |
Average Inventory |
38.54 | 34.02 | 27.95 | 26.37 | |
Average Assets |
1,720.41 | 1,606.17 | 1,701.95 | 1,724.39 | |
Average Common Equity |
1,132.57 | 992.72 | 1,021.35 | 1,063.68 |
Columns are period end dates